Portal de investigación
Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
BACKGROUND: The mechanisms underlying tumor evolution and treatment resistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are not fully understood. This study used whole-exome sequencing (WES) of paired tumor tissue and circulating tumor DNA (ctDNA) to analyze intratumoral heterogeneity (ITH) and clonal dynamics at diagnosis and relapse. PATIENTS AND METHODS: Between January 2017 and September 2022, we enrolled 152 patients with LA-HNSCC treated with radical chemoradiotherapy. Tumor tissue and plasma samples were collected at baseline and at relapse. WES was carried out on DNA extracted from tissue, plasma, and germline samples. Oncogenic variants were analyzed to evaluate tumor evolution and ITH. Concordance, pathway alterations, and associations with survival were examined. RESULTS: Out of the 152 patients selected, 81 were excluded based on clinical criteria. Of the 71 remaining patients, 37 had the complete set of samples of adequate quality for analysis. The most frequent mutations involved TP53 (48%), KMT2D (34%), and NOTCH1 (34%) at diagnosis. Pathogenic germline variants, including actionable mutations in BRCA2, CHK2, and KIT, were identified in 13.5% of cases. Concordance between tissue and plasma was low (median 11.8% at baseline, 12.4% at relapse), with up to 67% of oncogenic variants found only in ctDNA. Longitudinal analysis revealed limited overlap (10.3%) between baseline and relapse ctDNA, with some emerging resistance-associated mutations in PI3K-mTORC2 and ATM-CHK2 pathways. Alterations in IL6-JAK-STAT3 and RHO GTPase pathways were enriched in locoregional relapses (adjusted P < 0.001). Mutations in MMP15 and PTPRE were linked to shorter locoregional progression-free survival, whereas PDE2A mutations were associated with prolonged progression-free survival. CONCLUSIONS: WES of ctDNA uncovers extensive ITH and identifies molecular drivers of resistance not captured by tissue biopsies. These findings support the use of plasma ctDNA analysis to monitor tumor evolution and personalize follow-up in LA-HNSCC, especially given the anatomical complexity that often limits repeated tissue sampling.
Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 2059-7029, 2059-7029
- Tipo:
- Article
- Páginas:
- 105904-105904
- PubMed:
- 41270698
ESMO Open ELSEVIER
Documentos
- No hay documentos
Filiaciones
Keywords
- LA-HNSCC; biomarkers; ctDNA; intratumor heterogeneity; precision medicine
Financiación
Proyectos y Estudios Clínicos
Caracterización y abordaje de la enfermedad mínima residual en cáncer de colon localizado: un paso hacia la medicina de precisión.
Investigador/a Principal NOELIA TARAZONA LLAVERO
PI21/00689 . INSTITUTO SALUD CARLOS III . 2022
CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD
Investigador/a Principal BLANCA GARCÍA MICÓ
FI22/00267 . INSTITUTO SALUD CARLOS III . 2023
Descifrando la heterogeneidad tumoral mediante la biopsia líquida para abordar la enfermedad mínima residual en el cáncer de colon localizado.
Investigador/a Principal BELÉN MARTÍNEZ CASTEDO
FPU21/00373 . MINISTERIO EDUCACION, CULTURA Y DEPORTE . 2022
Enfoque integral de la enfermedad micrometastásica hepática en cáncer colorrectal: caracterización multiómica de metástasis, respuesta inmune y abordaje de la enfermedad residual.
Investigador/a Principal NOELIA TARAZONA LLAVERO
PI24/00103 . INSTITUTO SALUD CARLOS III . 2025
Cita
Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer. Bruixola G, Martín J, Gimeno F, Carbonell JA, García B, Martínez B, González D et al. ESMO Open. 2025 diciembre 01. 10 (12):105904-105904. DOI:10.1016/j.esmoop.2025.105904. PMID:41270698.
